1. Home
  2. VIVO vs NEPH Comparison

VIVO vs NEPH Comparison

Compare VIVO & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

VIVO

VivoPower PLC Ordinary Shares

N/A

Current Price

$4.59

Market Cap

37.5M

Sector

Utilities

ML Signal

N/A

Logo Nephros Inc.

NEPH

Nephros Inc.

HOLD

Current Price

$3.47

Market Cap

34.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VIVO
NEPH
Founded
2014
1997
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Power Generation
Medical/Dental Instruments
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
37.5M
34.0M
IPO Year
N/A
2004

Fundamental Metrics

Financial Performance
Metric
VIVO
NEPH
Price
$4.59
$3.47
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
1.7M
31.9K
Earning Date
05-23-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
1000.00
EPS
N/A
0.01
Revenue
N/A
$18,789,000.00
Revenue This Year
N/A
$11.24
Revenue Next Year
N/A
$11.58
P/E Ratio
N/A
$365.50
Revenue Growth
N/A
32.67
52 Week Low
$1.97
$2.28
52 Week High
$5.36
$6.42

Technical Indicators

Market Signals
Indicator
VIVO
NEPH
Relative Strength Index (RSI) 60.74 54.80
Support Level $2.87 $2.79
Resistance Level $5.25 $3.78
Average True Range (ATR) 0.56 0.36
MACD 0.11 0.04
Stochastic Oscillator 70.47 68.18

Price Performance

Historical Comparison
VIVO
NEPH

About NEPH Nephros Inc.

Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of revenue from product sales and a small amount from royalty revenue and other revenues.

Share on Social Networks: